GET DAILY SIGNALSUltragenyx (RARE) Delivers Q3 Revenue of $173 Million While Narrowing Losses
Key Takeaways
- Ultragenyx reported third-quarter 2026 total revenue of $173 million, up from $160 million a year earlier but below the roughly $182 million consensus estimate.
- Net loss narrowed to $118 million, or $1.16 per share, from $180 million, or $1.81 per share, in the prior-year quarter, still a wider loss than analysts expected.
- Crysvita revenue slipped to $109 million from $112 million, while Dojolvi ($30 million), Evkeeza ($24 million), and Mepsevii ($10 million) all grew year over year.
- Management reaffirmed 2026 revenue guidance of $730 million to $760 million and reiterated its goal of full-year GAAP profitability in 2027.
- The company announced a roughly 20% workforce reduction and lower planned 2027 operating expenses, alongside two new gene therapy approvals during the quarter.
- For more detail on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast.
- Discover actionable market ideas with Trending AI Robots.
Earnings Context and Why It Matters
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on rare and ultra-rare genetic diseases, a segment where a small patient base must support high-value, often curative therapies. This quarterly report matters because it tests whether the company's expanding commercial franchise can offset rising pipeline investment while it still posts losses. In the prior quarter, Ultragenyx delivered record revenue of $214 million, so the sequential decline into the third quarter raised questions about commercial momentum. Investors are also watching two newly approved gene therapies and a $413 million sale of priority review vouchers (PRVs) as signals of whether management can reach its 2027 profitability target.
Reported Results
For the third quarter of 2026, Ultragenyx reported total revenue of $173 million, an increase from $160 million in the year-ago period but below the consensus estimate of approximately $182 million. Net loss narrowed to $118 million, or $1.16 per share, compared with a net loss of $180 million, or $1.81 per share, a year earlier. Analysts had projected a smaller loss of about $1.10 per share, so the bottom line also fell short of expectations.
Revenue by product showed mixed results. Crysvita revenue declined to $109 million from $112 million. Dojolvi revenue rose to $30 million from $24 million, Evkeeza revenue increased to $24 million from $17 million, and Mepsevii revenue grew to $10 million from $7 million. Total operating expenses decreased to $283 million from $331 million, with research and development (R&D) expense falling to $154 million from $216 million, reflecting the company's cost-reduction initiatives. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Ultragenyx reaffirmed its full-year 2026 total revenue guidance of $730 million to $760 million, excluding potential revenue from new product launches, and reiterated its expectation of full-year GAAP (Generally Accepted Accounting Principles) profitability in 2027.
Market Reaction and Investor Sentiment
Investor sentiment heading into the report was cautious, with the stock already down sharply from its 52-week high. Shares closed at $16.69 ahead of the announcement, reflecting declines of roughly 36% over the prior three months and nearly 49% over the past year. After the results missed both revenue and earnings expectations, the stock fell about 6% in after-hours trading. The muted reaction reflects a tension between near-term execution and longer-term catalysts: investors are weighing the modest sequential revenue dip and lower Crysvita contribution against two landmark gene therapy approvals and a substantial capital infusion from PRV sales.
Forward Outlook and Key Factors to Monitor
Looking ahead, Ultragenyx is entering a pivotal period shaped by both cost discipline and new product launches. The company announced a workforce reduction of approximately 20% and plans to cut 2027 R&D expenses below $350 million and selling, general, and administrative (SG&A) expenses below $375 million, moves designed to narrow losses and support the 2027 profitability target.
On the commercial side, investors will watch the launch of Genglycos, approved for glycogen storage disease type Ia, and Fayuvi, the first treatment for Sanfilippo syndrome type A (MPS IIIA). Both were approved by the U.S. Food and Drug Administration (FDA) during the third quarter and represent the company's first gene therapy launches. Their uptake will be a key driver of whether Ultragenyx can exceed its 2026 guidance, which currently excludes new-launch revenue.
Other factors to monitor include Crysvita ordering patterns, particularly in Latin America and Turkey, continued Evkeeza expansion outside the United States, and any readouts from late-stage pipeline programs. The company's balance sheet remains a point of focus as well, with management reaffirming its path to profitability while balancing R&D investment against disciplined expense control.
Exploring AI Tools for Portfolio Monitoring
In my own research process, I find Tickeron’s AI Screener helpful for quickly scanning biotech names and spotting patterns that align with fundamental developments like those at Ultragenyx. It lets me filter by industry, volatility, and performance metrics in one place, which saves time when tracking multiple rare-disease stocks. The tool has become a regular part of how I cross-check earnings surprises against broader sector trends before adjusting any positions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RARE in +6.97% Uptrend, rising for three consecutive days on October 28, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RARE advanced for three days, in 219 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on RARE as a result. In 61 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Aroon Indicator entered an Uptrend today. In 155 of 226 cases where RARE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 59 cases where RARE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
RARE broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.522) is normal, around the industry mean (3.104). P/E Ratio (-2.796) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (1.809) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. RARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics for rare diseases
Industry Biotechnology
Advertisement